News brief­ing: Glax­o­SmithK­line adds to flur­ry of deal­mak­ing; Take­da strikes $322M deal to of­fload a non-core port­fo­lio

As 2020 winds down, British drug­mak­er Glax­o­SmithK­line con­tin­ues a flur­ry of biotech deal­mak­ing — this time fo­cused on small mol­e­cule ther­a­peu­tics that tar­get trans­mem­brane pro­teins.

Through a col­lab­o­ra­tion with San Diego-based Lig­and Phar­ma­ceu­ti­cals and its sub­sidiary Ica­gen, the groups will work to iden­ti­fy and de­vel­op in­hibitors of a spe­cif­ic ge­net­i­cal­ly-val­i­dat­ed mol­e­c­u­lar tar­get rel­e­vant to neu­ro­log­i­cal dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER